Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge
A phase 2 trial of Pembrolizumab, Lenvatinib in vulvar cancer, run by AGO Research GmbH, now recruiting.
Overview
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy is a phase 2 interventional study registered as NCT05903833 by AGO Research GmbH, with 42 participants planned, started 2025-06-24 and due to reach its primary completion in 2027-10-30. Interventions recorded: Pembrolizumab, Lenvatinib. Conditions listed: Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLEAP-002
Shares Lenvatinib, Pembrolizumab.
- TrialLITESPARK-012
Shares Lenvatinib, Pembrolizumab.
- TrialGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Shares Lenvatinib, Pembrolizumab.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Lenvatinib, Pembrolizumab.
- TrialA Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Shares Lenvatinib, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Shares Vulvar cancer, Pembrolizumab.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Lenvatinib, Pembrolizumab.
- TrialSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Shares Lenvatinib, Pembrolizumab.